Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPI-002 Intravitreal Implant for Cataract Progression Delay Post-Vitrectomy
NCT05026632Phase 2Completed
- Sponsor
- Nacuity Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Sep 2026
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NPI-002 in cataract, sponsored by Nacuity Pharmaceuticals. Started Jan 2022; status: completed.
02
Drugs
NPI-002
03
Conditions
cataract
Beyond the preview
Go deeper on NCT05026632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05026632.